Keywords: AstraZeneca, fulvestrant, Breast cancer, Research, Licensing partnerships,

Positive new data Ph III on AstraZeneca’s Faslodex presented at SABC; drugmaker seeks more partnerships

Article | 11 December 2009

Print This

Data from a new phase III study, presented for the first time yesterday at the annual San Antonio Breast Cancer ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in